New treatment strategies for COPD

References

• Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6): 932–46
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, et al; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163(5): 1256–76
   PubMedGoogle Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272(19): 1497–505
   PubMed Web of Science ®Google Scholar
• Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93(3): 391–8
   PubMed Web of Science ®Google Scholar
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1 (8222): 681–6
   PubMed Web of Science ®Google Scholar
• Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333(13): 817–22
   PubMed Web of Science ®Google Scholar
• Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Rockville, Md: US Dept Of Health and Human Services, Public Health Service, 2000
   Google Scholar
• Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153(3): 967–75
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158(5 Pt 1): 1557–65
   PubMed Web of Science ®Google Scholar
• Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(5): 1087–92
   PubMed Web of Science ®Google Scholar
• Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4): 1283–9
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2): 217–24
   PubMed Web of Science ®Google Scholar
• ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119(6): 1661–70
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340(25): 1948–53
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320(7245): 1297–303
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26): 1902–9
   PubMed Web of Science ®Google Scholar
• Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(4): 580–4
   PubMed Web of Science ®Google Scholar
• Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20(4): 819–25
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2): 196–204
   PubMed Web of Science ®Google Scholar
• Pulmonary rehabilitation—1999. American Thoracic Society. Am J Respir Crit Care Med 1999; 159(5 Pt 1): 1666–82
   Google Scholar
• Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995; 109(1): 106–16; discussion 116–9
   PubMed Web of Science ®Google Scholar
• Casaburi R, Porszasz J, Burns MR, et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155(5): 1541–51
   PubMed Web of Science ®Google Scholar
• Maltais F, LeBlanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154(2 Pt 1): 442–7
   PubMed Web of Science ®Google Scholar
• Celli BR. The clinical use of upper extremity exercise. Clin Chest Med 1994; 15(2): 339–49
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348(21): 2059–73
   PubMed Web of Science ®Google Scholar
• International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/Intemational Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998; 158(1): 335–9
   PubMedGoogle Scholar
• Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340(25): 1941–7
   PubMed Web of Science ®Google Scholar
• Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341(8860): 1555–7
   PubMed Web of Science ®Google Scholar
• Meecham Jones DJ, Paul EA, Jones PW, et al. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152(2): 538–44
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 2000; 118(6): 1582–90
   PubMed Web of Science ®Google Scholar